Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease

Human Molecular Genetics

Volumn 24, Issue 9, 2015, Pages 2508-2527

  Jin, Jing ^a   Peng, Qi ^a   Hou, Zhipeng ^a   Jiang, Mali ^a   Wang, Xin ^b   Langseth, Abraham J ^c   Tao, Michael ^a   Barker, Peter B ^a   Mori, Susumu ^a   Bergles, Dwight E ^c   Ross, Christopher A ^a,c   Detloff, Peter J ^d   Zhang, Jiangyang ^a   Duan, Wenzhen ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HUNTINGTIN; MYELIN; MYELIN BASIC PROTEIN; PHOSPHOPROTEIN DARPP 32; HTT PROTEIN, HUMAN; NERVE PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SIZE; CAG REPEAT; CELL PROLIFERATION; CONTROLLED STUDY; CORPUS CALLOSUM; FEMALE; GENE TARGETING; HD GENE HOMOLOG; HUNTINGTON CHOREA; IN VIVO STUDY; MALE; MOUSE; MYELIN SHEATH; MYELINATED NERVE; MYELINATION; NEURALGIA; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROCYTE PRECURSOR CELL; PARENT; PERINATAL PERIOD; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PSYCHOMOTOR DISORDER; RANDOMIZATION; SEQUENCE HOMOLOGY; STRIATE CORTEX; WHITE MATTER LESION; ALLELE; ANIMAL; ATROPHY; BRAIN; CORPUS STRIATUM; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; MUTATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIA; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PROTEINOSIS; TRANSGENIC MOUSE; WHITE MATTER;

ALLELES; ANIMALS; ATROPHY; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL PROLIFERATION; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION; MYELIN SHEATH; NERVE TISSUE PROTEINS; OLIGODENDROGLIA; ORGAN SIZE; PROTEIN AGGREGATION, PATHOLOGICAL; WHITE MATTER;

EID: 84940176784     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv016     Document Type: Article

References (89)

1. The Huntington's Disease Collaborative Research Group. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
2. Williams, A.J. and Paulson, H.L. (2008) Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci., 31, 521-528.
3. Crotti, A., Benner, C., Kerman, B.E., Gosselin, D., Lagier-Tourenne, C., Zuccato, C., Cattaneo, E., Gage, F.H., Cleveland, D.W. and Glass, C.K. (2014) Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat. Neurosci., 17, 513-521.
4. Rosas, H.D., Tuch, D.S., Hevelone, N.D., Zaleta, A.K., Vangel, M., Hersch, S.M. and Salat, D.H. (2006) Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov. Disord., 21, 1317-1325.
5. Magnotta, V.A., Kim, J., Koscik, T., Beglinger, L.J., Espinso, D., Langbehn, D., Nopoulos, P. and Paulsen, J.S. (2009) Diffusion tensor imaging in preclinical Huntington's disease. Brain Imaging Behav., 3, 77-84.
6. Vandenberghe, W., Demaerel, P., Dom, R. and Maes, F. (2009) Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease. J. Neurol., 256, 109-114.
7. Dumas, E.M., van den Bogaard, S.J., Ruber, M.E., Reilman, R.R., Stout, J.C., Craufurd, D., Hicks, S.L., Kennard, C., Tabrizi, S.J., van Buchem, M.A. et al. (2012) Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. Hum. Brain Mapp., 33, 203-212.
8. Tabrizi, S.J., Scahill, R.I., Durr, A., Roos, R.A., Leavitt, B.R., Jones, R., Landwehrmeyer, G.B., Fox, N.C., Johnson, H., Hicks, S.L. et al. (2011) Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol., 10, 31-42.
9. Aylward, E.H., Nopoulos, P.C., Ross, C.A., Langbehn, D.R., Pierson, R.K., Mills, J.A., Johnson, H.J., Magnotta, V.A., Juhl, A.R., Paulsen, J.S. et al. (2011) Longitudinal change in regional brain volumes in prodromal Huntington disease. J. Neurol. Neurosurg. Psychiatry., 82, 405-410.
10. Poudel, G., Stout, J.C., Dominguez, D.J., Salmon, L., Churchyard, A., Chua, P., Georgiou-Karistianis, N. and Egan, G.F. (2014) White matter connectivity reflects clinical and cognitive status in Huntington's disease. Neurobiol. Dis, 65, 180-187.
11. Novak, M.J., Seunarine, K.K., Gibbard, C.R., Hobbs, N.Z., Scahill, R.I., Clark, C.A. and Tabrizi, S.J. (2014) Whitematter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression. Cortex., 52, 98-112.
12. Curtis, M.A., Penney, E.B., Pearson, A.G., van Roon-Mom, W. M., Butterworth, N.J., Dragunow, M., Connor, B. and Faull, R. L. (2003) Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc. Natl Acad. Sci. USA, 100, 9023-9027.
13. Myers, R.H., Vonsattel, J.P., Paskevich, P.A., Kiely, D.K., Stevens, T.J., Cupples, L.A., Richardson, E.P. Jr. and Bird, E.D. (1991) Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J. Neuropathol. Exp. Neurol., 50, 729-742.
14. Ernst, A., Alkass, K., Bernard, S., Salehpour, M., Perl, S., Tisdale, J., Possnert, G., Druid, H. and Frisen, J. (2014) Neurogenesis in the striatum of the adult human brain. Cell, 156, 1072-1083.
15. Bartzokis, G., Lu, P.H., Tishler, T.A., Fong, S.M., Oluwadara, B., Finn, J.P., Huang, D., Bordelon, Y., Mintz, J. and Perlman, S. (2007) Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem. Res., 32, 1655-1664.
16. Heng, M.Y., Tallaksen-Greene, S.J., Detloff, P.J. and Albin, R.L. (2007) Longitudinal evaluation of the Hdh(CAG)150 knockin murine model of Huntington's disease. J. Neurosci., 27, 8989-8998.
17. Lee, C.Y., Cantle, J.P. and Yang, X.W. (2013) Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. FEBS J., 280, 4382-4394.
18. Menalled, L.B., Sison, J.D., Dragatsis, I., Zeitlin, S. and Chesselet, M.F. (2003) Time course of early motor and neuropathological anomalies in a knock-inmousemodel of Huntington's disease with 140 CAG repeats. J. Comp. Neurol., 465, 11-26.
19. Ferrante, R.J. (2009) Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim. Biophys. Acta, 1792, 506-520.
20. Heng, M.Y., Detloff, P.J. and Albin, R.L. (2008) Rodent genetic models of Huntington disease. Neurobiol. Dis., 32, 1-9.
21. Heng, M.Y., Duong, D.K., Albin, R.L., Tallaksen-Greene, S.J., Hunter, J.M., Lesort, M.J., Osmand, A., Paulson, H.L. and Detloff, P.J. (2010) Early autophagic response in a novel knock-in model of Huntington disease. Hum. Mol. Genet., 19, 3702-3720.
22. Heikkinen, T., Lehtimaki, K., Vartiainen, N., Puolivali, J., Hendricks, S.J., Glaser, J.R., Bradaia, A., Wadel, K., Touller, C., Kontkanen, O. et al. (2012) Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS One, 7, e50717.
23. Menalled, L.B., Kudwa, A.E., Miller, S., Fitzpatrick, J.,Watson-Johnson, J., Keating, N., Ruiz, M., Mushlin, R., Alosio, W., McConnell, K. et al. (2012) Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS One, 7, e49838.
24. Saleh, N., Moutereau, S., Durr, A., Krystkowiak, P., Azulay, J.P., Tranchant, C., Broussolle, E., Morin, F., Bachoud-Levi, A.C. and Maison, P. (2009) Neuroendocrine disturbances in Huntington's disease. PLoS One, 4, e4962.
25. Hodgson, J.G., Agopyan, N., Gutekunst, C.A., Leavitt, B.R., Le-Piane, F., Singaraja, R., Smith, D.J., Bissada, N., McCutcheon, K., Nasir, J. et al. (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron, 23, 181-192.
26. Li, H., Li, S.H., Johnston, H., Shelbourne, P.F. and Li, X.J. (2000) Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat. Genet., 25, 385-389.
27. Wheeler, V.C., White, J.K., Gutekunst, C.A., Vrbanac, V.,Weaver, M., Li, X.J., Li, S.H., Yi, H., Vonsattel, J.P., Gusella, J.F. et al. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet., 9, 503-513.
28. Menalled, L.B., Sison, J.D., Wu, Y., Olivieri, M., Li, X.J., Li, H., Zeitlin, S. and Chesselet, M.F. (2002) Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci., 22, 8266-8276.
29. Slow, E.J., van Raamsdonk, J., Rogers, D., Coleman, S.H., Graham, R.K., Deng, Y., Oh, R., Bissada, N., Hossain, S.M., Yang, Y.Z. et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 12, 1555-1567.
30. Van Raamsdonk, J.M., Murphy, Z., Slow, E.J., Leavitt, B.R. and Hayden, M.R. (2005) Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 14, 3823-3835.
31. DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P. and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277, 1990-1993.
32. Gutekunst, C.A., Li, S.H., Yi, H., Mulroy, J.S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R.J., Hersch, S.M. and Li, X.J. (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci., 19, 2522-2534.
33. Kuemmerle, S., Gutekunst, C.A., Klein, A.M., Li, X.J., Li, S.H., Beal, M.F., Hersch, S.M. and Ferrante, R.J. (1999) Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol., 46, 842-849.
34. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R. et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493-498.
35. Gauthier, L.R., Charrin, B.C., Borrell-Pages, M., Dompierre, J.P., Rangone, H., Cordelieres, F.P., De Mey, J., MacDonald, M.E., Lessmann, V., Humbert, S. et al. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell, 118, 127-138.
36. Powers, W.J., Videen, T.O., Markham, J., McGee-Minnich, L., Antenor-Dorsey, J.V., Hershey, T. and Perlmutter, J.S. (2007) Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc. Natl Acad. Sci. USA, 104, 2945-2949.
37. Provencher, S.W. (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med., 30, 672-679.
38. Paulsen, J.S., Nopoulos, P.C., Aylward, E., Ross, C.A., Johnson, H., Magnotta, V.A., Juhl, A., Pierson, R.K., Mills, J., Langbehn, D. et al. (2010) Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res. Bull., 82, 201-207.
39. Rosas, H.D., Lee, S.Y., Bender, A.C., Zaleta, A.K., Vangel, M., Yu, P., Fischl, B., Pappu, V., Onorato, C., Cha, J.H. et al. (2010) Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection". Neuroimage, 49, 2995-3004.
40. Weaver, K.E., Richards, T.L., Liang, O., Laurino, M.Y., Samii, A. and Aylward, E.H. (2009) Longitudinal diffusion tensor imaging in Huntington's Disease. Exp. Neurol., 216, 525-529.
41. Kloppel, S., Draganski, B., Golding, C.V., Chu, C., Nagy, Z., Cook, P.A., Hicks, S.L., Kennard, C., Alexander, D.C., Parker, G.J. et al. (2008) White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain, 131, 196-204.
42. Nucifora, P.G., Verma, R., Lee, S.K. and Melhem, E.R. (2007) Diffusion-tensor MR imaging and tractography: exploring brain microstructure and connectivity. Radiology, 245, 367-384.
43. Delmaire, C., Dumas, E.M., Sharman, M.A., van den Bogaard, S.J., Valabregue, R., Jauffret, C., Justo, D., Reilmann, R., Stout, J. C., Craufurd, D. et al. (2013) The structural correlates of functional deficits in early huntington's disease. Hum. Brain Mapp, 34, 2141-2153.
44. Curtis, M.A., Connor, B. and Faull, R.L. (2003) Neurogenesis in the diseased adult human brain-new therapeutic strategies for neurodegenerative diseases. Cell Cycle, 2, 428-430.
45. Nishiyama, A., Lin, X.H., Giese, N., Heldin, C.H. and Stallcup, W.B. (1996) Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. J. Neurosci. Res., 43, 299-314.
46. Rivers, L.E., Young, K.M., Rizzi, M., Jamen, F., Psachoulia, K., Wade, A., Kessaris, N. and Richardson, W.D. (2008) PDGFRA/ NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. Nat. Neurosci., 11, 1392-1401.
47. Kang, S.H., Fukaya, M., Yang, J.K., Rothstein, J.D. and Bergles, D.E. (2010) NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. Neuron, 68, 668-681.
48. Yang, Q.K., Xiong, J.X. and Yao, Z.X. (2013) Neuron-NG2 Cell Synapses: Novel Functions for Regulating NG2 Cell Proliferation and Differentiation. Biomed. Res. Int., 2013, 402843.
49. Richardson,W.D., Young, K.M., Tripathi, R.B. and McKenzie, I. (2011) NG2-glia as multipotent neural stem cells: fact or fantasy? Neuron, 70, 661-673.
50. Levine, J.M., Reynolds, R. and Fawcett, J.W. (2001) The oligodendrocyte precursor cell in health and disease. Trends Neurosci., 24, 39-47.
51. Gensert, J.M. and Goldman, J.E. (1997) Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron, 19, 197-203.
52. Keirstead, H.S., Levine, J.M. and Blakemore, W.F. (1998) Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord. Glia, 22, 161-170.
53. Dawson, M.R., Levine, J.M. and Reynolds, R. (2000) NG2-expressing cells in the central nervous system: are they oligodendroglial progenitors? J. Neurosci. Res., 61, 471-479.
54. Di Bello, I.C., Dawson, M.R., Levine, J.M. and Reynolds, R. (1999) Generation of oligodendroglial progenitors in acute inflammatory demyelinating lesions of the rat brain stem is associated with demyelination rather than inflammation. J. Neurocytol., 28, 365-381.
55. Martynoga, B., Morrison, H., Price, D.J. and Mason, J.O. (2005) Foxg1 is required for specification of ventral telencephalon and region-specific regulation of dorsal telencephalic precursor proliferation and apoptosis. Dev. Biol., 283, 113-127.
56. Nopoulos, P.C., Aylward, E.H., Ross, C.A., Mills, J.A., Langbehn, D.R., Johnson, H.J., Magnotta, V.A., Pierson, R.K., Beglinger, L. J., Nance, M.A. et al. (2011) Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain, 134, 137-142.
57. Sathasivam, K., Neueder, A., Gipson, T.A., Landles, C., Benjamin, A.C., Bondulich, M.K., Smith, D.L., Faull, R.L., Roos, R.A., Howland, D. et al. (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl Acad. Sci. USA, 110, 2366-2370.
58. Gipson, T.A., Neueder, A., Wexler, N.S., Bates, G.P. and Housman, D. (2013) Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis. RNA Biol., 10, 1647-1652.
59. Rosas, H.D., Goodman, J., Chen, Y.I., Jenkins, B.G., Kennedy, D. N., Makris, N., Patti, M., Seidman, L.J., Beal, M.F. and Koroshetz, W.J. (2001) Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology, 57, 1025-1028.
60. Rosas, H.D., Doros, G., Gevorkian, S., Malarick, K., Reuter, M., Coutu, J.P., Triggs, T.D., Wilkens, P.J., Matson, W., Salat, D.H. et al. (2014) PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology, 82, 850-857.
61. Glodzik-Sobanska, L., Slowik, A., Borratynska, A. and Szczudlik, A. (2003) Depressive symptoms following ischemic stroke. Neurol. Neurochir. Pol., 37, 17-25.
62. Ross, C.A. (2002) Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron, 35, 819-822.
63. Lu, B. (2003) BDNF and activity-dependent synaptic modulation. Learn. Mem., 10, 86-98.
64. Baquet, Z.C., Gorski, J.A. and Jones, K.R. (2004) Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci., 24, 4250-4258.
65. Sanchez-Pernaute, R., Garcia-Segura, J.M., del Barrio Alba, A., Viano, J. and de Yebenes, J.G. (1999) Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology, 53, 806-812.
66. Reynolds, N.C. Jr., Prost, R.W. and Mark, L.P. (2005) Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res., 1031, 82-89.
67. Sturrock, A., Laule, C., Decolongon, J., Dar Santos, R., Coleman, A.J., Creighton, S., Bechtel, N., Reilmann, R., Hayden, M.R., Tabrizi, S.J. et al. (2010) Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology, 75, 1702-1710.
68. van den Bogaard, S.J., Dumas, E.M., Teeuwisse,W.M., Kan, H. E., Webb, A., Roos, R.A. and van der Grond, J. (2011) Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism. J. Neurol., 258, 2230-2239.
69. Unschuld, P.G., Edden, R.A., Carass, A., Liu, X., Shanahan, M., Wang, X., Oishi, K., Brandt, J., Bassett, S.S., Redgrave, G.W. et al. (2012) Brain metabolite alterations and cognitive dysfunction in early Huntington's disease. Mov. Disord., 27, 895-902.
70. Gramsbergen, J.B., Veenma-Van der Duin, L., Venema, K. and Korf, J. (1986) Cerebral cation shifts and amino acids in Huntington's disease. Arch. Neurol., 43, 1276-1281.
71. Zacharoff, L., Tkac, I., Song, Q., Tang, C., Bolan, P.J., Mangia, S., Henry, P.G., Li, T. and Dubinsky, J.M. (2012) Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease. J. Cereb. Blood Flow. Metab., 32, 502-514.
72. Tkac, I., Henry, P.G., Zacharoff, L.,Wedel, M., Gong,W., Deelchand, D.K., Li, T. and Dubinsky, J.M. (2012) Homeostatic adaptations in brain energy metabolism in mouse models of Huntington disease. J. Cereb. Blood Flow. Metab., 32, 1977-1988.
73. Paulsen, J.S., Langbehn, D.R., Stout, J.C., Aylward, E., Ross, C. A., Nance, M., Guttman, M., Johnson, S., MacDonald, M., Beglinger, L.J. et al. (2008) Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry, 79, 874-880.
74. Tabrizi, S.J., Langbehn, D.R., Leavitt, B.R., Roos, R.A., Durr, A., Craufurd, D., Kennard, C., Hicks, S.L., Fox, N.C., Scahill, R.I. et al. (2009) Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol., 8, 791-801.
75. Gomez-Tortosa, E., MacDonald, M.E., Friend, J.C., Taylor, S.A., Weiler, L.J., Cupples, L.A., Srinidhi, J.,Gusella, J.F., Bird, E.D.,Vonsattel, J.P. et al. (2001) Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann. Neurol., 49, 29-34.
76. Stoffers, D., Sheldon, S., Kuperman, J.M., Goldstein, J., Corey-Bloom, J. and Aron, A.R. (2010) Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study. Neurology, 74, 1208-1216.
77. Xiang, Z., Valenza, M., Cui, L., Leoni, V., Jeong, H.K., Brilli, E., Zhang, J., Peng, Q., Duan, W., Reeves, S.A. et al. (2011) Peroxisome-proliferator-activated receptor gamma coactivator 1 alpha contributes to dysmyelination in experimental models of Huntington's disease. J. Neurosci., 31, 9544-9553.
78. Griffiths, I., Klugmann, M., Anderson, T., Yool, D., Thomson, C., Schwab, M.H., Schneider, A., Zimmermann, F., McCulloch, M., Nadon, N. et al. (1998) Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science, 280, 1610-1613.
79. Lappe-Siefke, C., Goebbels, S., Gravel, M., Nicksch, E., Lee, J., Braun, P.E., Griffiths, I.R. and Nave, K.A. (2003) Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet., 33, 366-374.
80. Kassmann,C.M., Lappe-Siefke, C., Baes,M., Brugger, B.,Mildner, A.,Werner, H.B., Natt, O., Michaelis, T., Prinz,M., Frahm, J. et al. (2007) Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat. Genet., 39, 969-976.
81. Yin, X., Crawford, T.O., Griffin, J.W., Tu, P., Lee, V.M., Li, C., Roder, J. and Trapp, B.D. (1998) Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J. Neurosci., 18, 1953-1962.
82. Nave, K.A. (2010) Myelination and the trophic support of long axons. Nat. Rev. Neurosci., 11, 275-283.
83. Nave, K.A. (2010) Oligodendrocytes and the "micro brake" of progenitor cell proliferation. Neuron, 65, 577-579.
84. Lin, C.H., Tallaksen-Greene, S., Chien,W.M., Cearley, J.A., Jackson, W.S., Crouse, A.B., Ren, S., Li, X.J., Albin, R.L. andDetloff, P.J. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet., 10, 137-144.
85. Dixon, K.T., Cearley, J.A., Hunter, J.M. and Detloff, P.J. (2004) Mouse Huntington's disease homologmRNAlevels: variation and allele effects. Gene Expr., 11, 221-231.
86. Provencher, S.W. (2001) Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed., 14, 260-264.
87. Kuo,Y.T.,Herlihy, A.H., So, P.W., Bhakoo, K.K. and Bell, J.D. (2005) In vivomeasurements of T1 relaxation times inmouse brain associated with different modes of systemic administration of manganese chloride. J. Magn. Reson. Imaging, 21, 334-339.
88. Duan,W., Peng, Q., Masuda, N., Ford, E., Tryggestad, E., Ladenheim, B., Zhao, M., Cadet, J.L., Wong, J. and Ross, C.A. (2008) Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol. Dis., 30, 312-322.
89. Dugas, J.C. and Emery, B. (2013) Purification of oligodendrocyte precursor cells from rat cortices by immunopanning. Cold Spring Harb. Protoc., 2013, 745-758.